(VIANEWS) – Shares of TherapeuticsMD (NASDAQ: TXMD) slid by a staggering 20.86% in 10 sessions from $5.32 at 2022-11-17, to $4.21 at 15:11 EST on Thursday, after five sequential sessions in a row of losses. NASDAQ is rising 0.99% to $11,285.32, after two consecutive sessions in a row of gains.
TherapeuticsMD’s last close was $4.21, 89.06% under its 52-week high of $38.50.
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, TherapeuticsMD has a trailing twelve months EPS of $-0.666.
TherapeuticsMD’s value is way under its 50-day moving average of $7.15 and way below its 200-day moving average of $10.00.
Annual Top and Bottom Value
TherapeuticsMD stock was valued at $4.21 as of 15:11 EST. This is way lower than its 52 week high of $38.50, and much higher than its 52 week low of $1.99.
More news about TherapeuticsMD (TXMD).